RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma
Sara Egea‐Rodriguez(West German Heart and Vascular Center Essen), Iris Helfrich(West German Heart and Vascular Center Essen)
Cited by 2
Related Papers
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain
|Frontiers in Immunology|2020|38
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
|Journal for ImmunoTherapy of Cancer|2023|29